Tiny Redx slammed af­ter first pa­tient is hit by ad­verse events, forc­ing a halt to can­cer drug study

The mi­cro­cap biotech Redx has lurched from a fi­nan­cial pick­le straight in­to a dam­ag­ing safe­ty is­sue with its lead drug.

The UK biotech has sus­pend­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.